Boettcher Lab

Associate Professor @UZH_en @Unispital_USZ @CCCZ_USZ studying the pathogenesis of cancer with a particular focus on TP53-mutant myeloid (pre-)malignancies

[Boettcher Lab @TheBoettcherLab]

🔥New paper from our lab @UZH_en @Unispital_USZ @CCCZ_USZ 🔥
#ERCC6L2 disease is a relatively recently described inherited bone marrow failure syndrome. It is strongly associated with somatic #TP53mutations and #AML or #MDS development. 1/7

https://t.co/RCjzmBnb0Z

[Inigo Martincorena @imartincorena]

Excited to share our latest work. Applying advanced single-molecule and single-cell DNA sequencing methods, we uncover an extraordinary landscape of somatic mutations in immune checkpoint genes in autoimmune lymphocytes. [1/n] https://t.co/8kQZ0NWl7X

[Blood Journals Portfolio @BloodPortfolio]

Ercc6l2 deficiency leads to replication stress, p53 pathway activation, and decreased Runx1 and Gata1 expression resulting in BMF. Read the plenary paper in Blood: https://t.co/tjdpXh2Nfk #plenarypaper #bloodjournal #p53

[Boettcher Lab @TheBoettcherLab]

I’m also very delighted to share the news that I have been promoted to #AssociateProfessor. @UZH_en @Unispital_USZ @CCCZ_USZ 🍾🥂🎉

[Boettcher Lab @TheBoettcherLab]

Bonus 2/2: Thanks to #Dr. James D. Griffin for featuring our work on the @BloodPortfolio podcast. https://t.co/mcpxda1VVQ

[Boettcher Lab @TheBoettcherLab]

🔥New paper from our lab @UZH_en @Unispital_USZ @CCCZ_USZ 🔥
#ERCC6L2 disease is a relatively recently described inherited bone marrow failure syndrome. It is strongly associated with somatic #TP53mutations and #AML or #MDS development. 1/7

https://t.co/RCjzmBnb0Z

[Boettcher Lab @TheBoettcherLab]

Bonus 1/2: Thanks to #Timothy_Chlon for his insightful commentary on our work!
https://t.co/6VahvBwi7I

[Boettcher Lab @TheBoettcherLab]

@myllymaki_mikko @Syopasaatio @LaaketieteenS @SuomenAkatemia @helsinkiuni Congratulations, Mikko! Well deserved! Looking forward to all the great science!

[ESH (Haematology) @ESHaematology]

Welcome to #ESHAL2026!
Stay tuned! ESH Young Scientific Reporters @DKotsos & @TanMeg9595 will provide regular updates on the conference!
February 27-March 1, 2026
Chairs: @DombretHerve, Christoph Röllig, @DrWendyStock
#ESHCONFERENCES #leusm
@Hemasphere_EHA

[Boettcher Lab @TheBoettcherLab]

Getting started for #ESHAL2026 @ESHaematology.

[Elizabeth McKenna @ElizSMcKenna]

Now online in @CD_AACR: Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators - by @FerranFeceCruz, @AndreasVarkaris, @aparna1024, Ryan Corcoran, and colleagues https://t.co/812WJZ932r @MassGenBrigham @MGBResearchNews @harvardmed

[Boettcher Lab @TheBoettcherLab]

@brummendorf Thank you so much, Tim!

[Boettcher Lab @TheBoettcherLab]

1/🔥 New paper from our lab!
#TP53-mutant clonal hematopoiesis (#CH) greatly increases risk for therapy-related #AML/MDS - but why?
We set out to dissect how mono- vs. biallelic #TP53 mutations drive leukemic evolution. https://t.co/bE4aSD61AG

[Boettcher Lab @TheBoettcherLab]

@SanjayPatelMD Thank you so much for putting these findings in context! I have the impression that even when formal AEL criteria aren’t met, TP53-mutant myeloid neoplasms often show erythroid-dominant marrow findings. IMHO an under-appreciated pattern.

[Boettcher Lab @TheBoettcherLab]

@DrKTakahashi Thank you so much!

[Boettcher Lab @TheBoettcherLab]

8/🍾🎉 Congratulations to #JonasFullin and the entire team, and many thanks to all collaborators!
📄 Read the full paper here:
“The pathogenesis of therapy-related myeloid neoplasms from TP53-mutant clonal hematopoiesis” https://t.co/bE4aSD61AG

[Boettcher Lab @TheBoettcherLab]

7/🎯 Take-home message:
Biallelic #TP53 inactivation is the key driver of leukemic transformation from CH → t-AML/MDS.
Non-mutational p53 inactivation matters (as recently shown #PMID: 40315418)
Findings support biallelic #TP53-mutant AML/MDS as a distinct biological entity.